JUPITER NEUROSCIENCES, INC.

false 0001679628 0001679628 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 17, 2026 Date of Report (Date of earliest event reported) JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41265 47-4828381 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1001 North US HWY 1 , Suite 504 , Jupiter , FL 33477 (Address of principal executive offices) (Zip Code) (561) 406-6154 Registrant’s telephone number, including area code Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock JUNS Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 17, 2026, Allison W. Brady, a member of the Board of Directors (the “Board”) of Jupiter Neurosciences, Inc. (the “Company”), informed the Company of her decision to resign from the Board, effective immediately. Ms. Brady also resigned from her positions as a member of the Audit Committee and the Compensation Committee of the Board, effective as of the same date. Her decision to resign is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Ms. Brady’s seat on the Board will remain vacant until the Company’s annual meeting on July 22, 2026. Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JUPITER NEUROSCIENCES, INC. Date: June 22, 2026 By: /s/ Christer Rosén Name: Christer Rosén Title: Chief Executive Officer